Vanessa Burrows

Vanessa Burrows represents clients in healthcare regulatory matters, including those involving the Food and Drug Administration (FDA). Vanessa has advised pharmaceutical and medical device manufacturers, healthcare and technology companies, and healthcare providers in connection with regulatory and compliance needs, as well as in M&A and capital-raising transactions. Vanessa has extensive experience counseling clients with respect to FDA enforcement matters, health privacy, security and breach issues, healthcare fraud and abuse matters. Some of her recent transactions have included representing Medline, Amneal, GMR Solutions, Teleflex, Waystar, Karuna Therapeutics, Advanced Instruments, Change Healthcare, Microsoft, CSL Behring, PPD, NeueHealth, and Bright Spring Health Services.

Joined the Firm, 2019; Partner, 2024

• American University Washington College of Law, Health Law and Policy Program Alumni Advisory Council, Chair (2026-2027)

• American Health Law Association, Fundamentals of Health Law Program Planning Committee

• International Bar Association, Technology Law Committee, Vice Chair of the Life Sciences Subcommittee

• Food and Drug Law Institute

• American Bar Association, Health Law and Administrative Law and Regulatory Practice Sections

• Health Law Handbook (2025-2026 ed.), Digital Health & Artificial Intelligence chapter

• Law360, “Navigating The Expanding Frontier Of Premerger Notice Laws,”

• Journal of Health Care Law and Policy, “Cannabis Considerations for Health Care Entities”

• Law360, “2 Bills Reflect Gov’t Interest in Health PE Investments”

B.A, magna cum laude, Valparaiso University (2001); M.A., with honors, Queen’s University Belfast (2002); J.D., cum laude, American University, Washington College of Law (2006).